Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

KPRX

Kiora Pharmaceuticals Inc

2.57

Aug 21 • 9:15 AM ET -0.05 (-1.91%)

Healthcare Biotechnology USA Nano NASD

Aug 19, 7:05 AMKiora licenses South Korean KIO-301 ophthalmic rights to Chong Kun Dang Pharmaceutical in deal with $1M upfront plus milestone and royalty potential

Peers: AIM APRE BCDA BIVI GOVX JAGX KAPA NEUP CALC CVM

| Held by: VXF DFAC DCOR

Scroll to Statements

Index	-
Market Cap	11.37M
Enterprise Value	-5.14M
Income	-10.99M
Sales	0.00M
Book/sh	3.81
Cash/sh	3.81
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	13
IPO	Feb 13, 2015

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	0.67
P/C	0.68
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	8.97
Current Ratio	8.97
Debt/Eq	0.02
LT Debt/Eq	0.01
Option/Short	No / Yes

EPS (ttm)	-2.64
EPS next Y	-0.85
EPS next Q	-0.38
EPS this Y	36.74%
EPS next Y	49.10%
EPS next 5Y	28.62%
EPS past 3/5Y	75.03% 65.58%
Sales past 3/5Y	- -
EPS Y/Y TTM	19.38%
Sales Y/Y TTM	-100.00%
EPS Q/Q	37.64%
Sales Q/Q	-
Earnings	Aug 07 BMO
EPS/Sales Surpr.	27.66% -

Insider Own	5.81%
Insider Trans	0.00%
Inst Own	39.85%
Inst Trans	-10.10%
ROA	-39.43%
ROE	-56.36%
ROIC	-64.56%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	-0.28%
SMA50	0.25%
SMA200	11.19%
Trades

Shs Outstand	4.43M
Shs Float	4.17M
Short Float	0.09%
Short Ratio	0.16
Short Interest	0.00M
52W High	2.95 -12.88%
52W Low	1.76 45.65%
Volatility	4.86% 4.02%
ATR (14)	0.10
RSI (14)	49.34
Beta	-0.33
Rel Volume	0.10
Avg Volume	23.50K
Volume	121

Perf Week	0.78%
Perf Month	2.80%
Perf Quarter	-4.10%
Perf Half Y	29.80%
Perf YTD	30.46%
Perf Year	-1.91%
Perf 3Y	-45.09%
Perf 5Y	-99.53%
Perf 10Y	-99.97%
Recom	1.00
Target Price	12.00
Prev Close	2.62
Price	2.57
Change %	-1.91%

Aug-19-26 07:00AM	Kiora Pharmaceuticals Licenses South Korean Ophthalmic Development and Commercialization Rights for KIO-301 to Chong Kun Dang Pharmaceutical Corporation (Newsfile)
Aug-07-26 07:00AM	Kiora Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Corporate Update (Newsfile Corp.)
Jul-15-26 02:25PM	SS Innovations International (SSII) Appoints Sarah Romano as Chief Financial Officer (NewMediaWire)
01:03AM	SS Innovations names Sarah Romano as CFO (MedTech Dive)
Jul-02-26 07:00AM	Kiora Pharmaceuticals to Participate in Piper Sandler Virtual Ophthalmology Symposium (Newsfile Corp.)
07:00AM	Loading…
Jun-18-26 07:00AM	Kiora Pharmaceuticals Reports its Ion Channel Modulator, KIO-300, Suppressed Seizure Activity in Preclinical Epilepsy Model (Newsfile)
May-08-26 07:00AM	Kiora Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Corporate Update (Newsfile)
Apr-14-26 07:00AM	Kiora's Phase 1 ABACUS Study of KIO-301 in Retinitis Pigmentosa Published in Nature Medicine; Phase 2 Trial Underway (Newsfile)
Apr-07-26 07:00AM	Kiora Pharmaceuticals Announces Private Placement for Up to $24 Million Led by Perceptive Advisors (Newsfile) +6.93%
Apr-02-26 04:30PM	Kiora Pharmaceuticals Announces Management Team Changes (Newsfile Corp.)
Mar-25-26 07:00AM	Kiora Pharmaceuticals Reports Fourth-Quarter and Full-Year 2025 Results; Company Advances Retinal Disease Pipeline with Two Active Phase 2 Clinical Trials (Newsfile)
Feb-19-26 08:30AM	Kiora Pharmaceuticals to Present at Oppenheimer's 36th Annual Healthcare Life Sciences Conference (Newsfile)
Jan-27-26 07:00AM	Retinal Disease Expert Dr. Taiji Sakamoto Joins Kiora Pharmaceuticals' Scientific Advisory Board (Newsfile)
Dec-01-25 06:45AM	Kiora Pharmaceuticals Granted U.S. Patent Covering Additional Formulations for the KIO-100 Family of Anti-Inflammatory Compounds (Newsfile)
Nov-07-25 06:00AM	Kiora Pharmaceuticals Reports Third Quarter 2025 Results; Company Advances Pipeline with Two Actively Enrolling Phase 2 Clinical Trials for Retinal Diseases (Newsfile)
09:00AM	Loading…
Oct-30-25 09:00AM	Kiora Pharmaceuticals Joins RARE-X Vision Consortium Promoting Collaboration and Development of New Treatments for Rare Ocular Disorders (PR Newswire)
Oct-15-25 07:00AM	Kiora Pharmaceuticals to Participate in the 2025 Maxim Growth Summit and Eyecelerator @ AAO 2025 (Newsfile)
Sep-04-25 07:00AM	Kiora Pharmaceuticals to Webcast On-Demand Presentation at The H.C. Wainwright 27th Annual Global Investment Conference (Newsfile)
Aug-08-25 07:00AM	Kiora Pharmaceuticals Reports Second Quarter 2025 Results; Company Advances Pipeline with Two Active Phase 2 Clinical Trials for Retinal Diseases (Newsfile)
Aug-07-25 07:00AM	Kiora Pharmaceuticals to Showcase Its Retinal Disease Therapeutic Pipeline at The H.C. Wainwright 5th Annual Ophthalmology Virtual Conference (Newsfile)
Aug-01-25 11:51AM	Vicarious Surgical names Stephen From as next CEO (MedTech Dive)
Jul-31-25 04:30PM	Vicarious Surgical Announces Leadership Transition: Stephen From, Healthcare Industry Veteran, Appointed Chief Executive Officer (Business Wire)
Jul-22-25 08:55AM	Kiora Pharmaceuticals Granted U.S. Patent Expanding Protection for KIO-104 in the Treatment of Ocular Disease (Newsfile)
Jul-16-25 12:00PM	Kiora Pharmaceuticals (KPRX) Upgraded to Strong Buy: Here's What You Should Know (Zacks) +5.00%
Jun-03-25 07:00AM	Kiora Pharmaceuticals and Senju Pharmaceutical Partner on KIO-301 for the Treatment of Retinal Diseases in Asia (Newsfile) +36.84%
May-09-25 07:00AM	Kiora Pharmaceuticals Reports First Quarter Results; Initiating Two Phase 2 Trials for Treatment of Retinal Diseases; Cash and Short-term Investments Expected to Fund Operations into Late 2027 (Newsfile)
May-05-25 07:00AM	Kiora Pharmaceuticals Presents In Vivo Preclinical Data at ARVO 2025 Demonstrating the Potential of KIO-104 to Treat Proliferative Vitreoretinopathy (Newsfile)
Apr-04-25 07:00AM	Kiora Pharmaceuticals to Present at The 24th Annual Needham Virtual Healthcare Conference (Newsfile) -7.31%
Mar-25-25 07:00AM	Kiora Pharmaceuticals Reports 2024 Results; Retinal Disease Drug Development Pipeline Continues to Advance; Cash and Short-Term Investments Expected to Fund Operations into 2027 (Newsfile) -5.00%
Mar-12-25 07:00AM	Kiora Pharmaceuticals to Present Preclinical Data on KIO-104 for the Treatment of Proliferative Vitreoretinopathy at the ARVO 2025 Annual Meeting (Newsfile)
07:00AM	Loading…
Feb-13-25 07:00AM	Kiora Pharmaceuticals Secures U.S. Composition-of-Matter Patent Expanding Protection of Its Anti-Inflammatory Compound KIO-104 (Newsfile)
Feb-11-25 06:45AM	Kiora Receives Approval to Initiate KLARITY, a Phase 2 Clinical Trial of KIO-104 for the Treatment of Retinal Macular Edema (Newsfile) -9.44%
Nov-08-24 07:00AM	Kiora Pharmaceuticals Reports Third Quarter Results; Retinal Disease Pipeline Advancing Two Phase 2 Studies (Newsfile)
Oct-30-24 07:28AM	Kiora Pharmaceuticals Gains Approval for Phase 2 Trial (TipRanks)
Oct-29-24 06:45AM	Kiora Pharmaceuticals Receives Investigational New Drug Approval to Initiate ABACUS-2, a Phase 2 Clinical Trial of KIO-301 for the Treatment of Retinitis Pigmentosa (Newsfile)
Sep-25-24 09:55AM	Kiora Pharmaceuticals to Participate in Upcoming Investor Conferences (Newsfile)
Aug-09-24 02:53PM	KPRX Stock Earnings: Kiora Pharmaceuticals Beats EPS for Q2 2024 (InvestorPlace)
07:00AM	Kiora Pharmaceuticals Reports Second Quarter Results; Retinal Disease Drug Development Pipeline Advancing Toward Two Phase 2 Studies (Newsfile)
Aug-06-24 07:03AM	Kiora Pharmaceuticals to Participate in Upcoming Investor Conferences (Newsfile)
Jul-30-24 06:45AM	Kiora Pharmaceuticals Receives European Orphan Medicinal Product Designation for KIO-301 for the Treatment of Inherited Retinal Dystrophies (Newsfile)
Jul-10-24 07:00AM	Kiora Pharmaceuticals to Participate in Jones Healthcare Seaside Summit 2024; Kiora Invites Investors to Submit Questions Following the Conference Presentation (Newsfile)
Jul-01-24 06:54AM	Biotech Executive Lisa Walters-Hoffert Joins Kiora Pharmaceuticals' Board of Directors (Newsfile)
Jun-25-24 06:45AM	Vitreoretinal Surgeon and Key Thought Leader Roger Goldberg, M.D., Joins Kiora Pharmaceuticals' Scientific Advisory Board (Newsfile)
Jun-18-24 09:40AM	Is Kiora Pharmaceuticals (KPRX) Stock Undervalued Right Now? (Zacks)
May-29-24 06:44PM	Lytham Partners Spring 2024 Investor Conference Starts Tomorrow, May 30, 2024 (Newsfile) -6.36%
May-20-24 07:00AM	Kiora Pharmaceuticals to Participate in Upcoming Investor Conferences (Newsfile)
May-10-24 01:54PM	KPRX Stock Earnings: Kiora Pharmaceuticals Beats EPS for Q1 2024 (InvestorPlace)
07:00AM	Kiora Pharmaceuticals Reports First Quarter Results; Update on Pipeline of Drugs Targeting Retinal Disease (Newsfile)
May-08-24 07:00AM	Kiora Pharmaceuticals to Present at The Citizens JMP Life Sciences Conference (Newsfile)
May-06-24 07:00AM	Kiora Pharmaceuticals Reports Additional Clinical Data for KIO-301 Showing a Statistically Significant Increase in Brain Activity in the Visual Cortex in Patients with Retinitis Pigmentosa (Newsfile)
Apr-11-24 07:00AM	Kiora Pharmaceuticals Receives Grant from Choroideremia Research Foundation to Fund Novel Clinical Trial Endpoints for Inherited Retinal Diseases; Approval Granted to Initiate Clinical Validation Study (Newsfile)
Apr-05-24 07:00AM	Kiora Pharmaceuticals to Present at Upcoming Investor Conferences (Newsfile)
Mar-28-24 06:45AM	Kiora Pharmaceuticals to Present Additional Data from Its ABACUS-1 Trial in Retinitis Pigmentosa at the ARVO 2024 Annual Meeting (Newsfile) +14.41%
Mar-25-24 07:00AM	Kiora Pharmaceuticals Reports 2023 Results; Continues to Advance Pipeline of Treatments for Rare Retinal Diseases (Newsfile)
Mar-08-24 07:00AM	Kiora Announces Publication of Phase 1 Study Demonstrating Safety, Tolerability and Anti-Inflammatory Activity of KIO-101 in the Treatment of Inflammation of the Eye (Newsfile)
Feb-01-24 08:14AM	Why Is Kiora Pharmaceuticals (KPRX) Stock Up 39% Today? (InvestorPlace) +53.87%
Jan-31-24 06:40PM	Kiora Pharmaceuticals Announces Private Placement of up to Approximately $45 Million (Newsfile) -6.20%
05:15PM	Kiora Pharmaceuticals and Th a Open Innovation Enter Strategic Agreement to Develop and Commercialize KIO-301 for the Treatment of Inherited Retinal Diseases; Total Deal Value of up to $301 Million includes $16 Million Upfront, up to $285 Million in Clinical Development, Regulatory and Commercial Milestones, Plus Commercial Royalties (Newsfile)
Nov-17-23 01:54PM	Breaking ground in vision restoration: Kiora Pharmaceuticals reveals promising results with KIO-301 (News Direct)
Nov-09-23 07:18AM	Kiora Pharmaceuticals Reports Q3 2023 Results; Expanding Clinical Development of KIO-301 for Inherited Retinal Diseases Based on Encouraging Results of ABACUS-1 Study in Retinitis Pigmentosa (Newsfile)
Nov-04-23 12:15PM	AAO Late-Breaking: Kiora's Small Molecule Photoswitch Demonstrates Meaningful Vision Improvements in Blind Patients with Retinitis Pigmentosa (Newsfile)
Oct-16-23 07:00AM	Kiora Pharmaceuticals to Participate in the Lytham Partners Fall 2023 Investor Conference (Newsfile) -5.30%
Oct-03-23 07:00AM	Kiora Pharmaceuticals Receives Investigational New Drug Application Approval to Expand Phase 1b Study of KIO-301 in Inherited Retinal Diseases; To Enroll Patients with Choroideremia and Additional Patients with Late-Stage Retinitis Pigmentosa (Newsfile)
Sep-21-23 07:00AM	Kiora Pharmaceuticals Appoints Praveen Tyle, PhD, as New Chairman; Succeeds Paul Chaney Who is Retiring After Serving 17 Years (Newsfile)
Sep-18-23 07:00AM	Kiora Pharmaceuticals Completes Last Patient, Last Visit in Phase 1B Trial of KIO-301 in Patients with Retinitis Pigmentosa (Newsfile)
Sep-14-23 07:01AM	Kiora Pharmaceuticals to Present Topline Results from the ABACUS Study at American Academy Ophthalmology (AAO); Phase 1b Study Evaluating KIO-301 in Retinitis Pigmentosa (Newsfile)
Sep-01-23 07:00AM	Kiora Pharmaceuticals Adjourns Special Meeting of Stockholders to September 27 (Newsfile)
Aug-29-23 01:43PM	Kiora Pharmaceuticals and the Choroideremia Research Foundation to Host Webinar on the Development of Molecular Photoswitches for Inherited Retinal Diseases (Newsfile)
Aug-23-23 07:33PM	Is Kiora Pharmaceuticals Significantly Undervalued? A Comprehensive Valuation Analysis (GuruFocus.com) +22.55% -16.80%
07:00AM	Kiora Pharmaceuticals Granted U.S. and European Patents for Local Ocular Delivery of the KIO-100 Family of Compounds; New IP Specifically Includes Treatment of Posterior Non-Infectious Uveitis (Newsfile)
Aug-22-23 01:06PM	Kiora Pharmaceuticals Taps B2i Digital to Deploy Data-Driven Investor Awareness Program (Newsfile)
Aug-16-23 07:00AM	Kiora Pharmaceuticals Webcasts Its Investor Presentation from the H.C. Wainwright 3rd Annual Ophthalmology Virtual Conference (Newsfile)
Aug-08-23 07:00AM	Kiora Pharmaceuticals Announces Q2 2023 Earnings and Business Update, Highlighting Pipeline Updates and Clinical Development Progress (Newsfile)
Aug-03-23 07:00AM	Kiora Pharmaceuticals, Inc. and Choroideremia Research Foundation Partner to Advance Novel Choroideremia Treatment (Newsfile)
Aug-01-23 07:00AM	Biotech Leader Carmine Stengone Joins Kiora Pharmaceuticals' Board of Directors (Newsfile)
Jul-05-23 07:00AM	Kiora Pharmaceuticals Receives $1.2 Million in Research Tax Credits to Advance the Treatment of Ophthalmic Disease (Newsfile)
Jun-23-23 08:35AM	Life Science Investor Forum: Presentations Now Available for Online Viewing (GlobeNewswire) -6.57%
Jun-20-23 10:58AM	Life Science Investor Forum Agenda Announced for June 22nd (GlobeNewswire) -7.68%
Jun-15-23 07:00AM	Kiora Pharmaceuticals and Sentrx Animal Care Amend Existing Manufacturing Licensing Agreement for KIO-201 (Newsfile) +5.49%
Jun-14-23 08:00AM	Kiora Pharmaceuticals to Present at Upcoming Investor Conferences (Newsfile)
Jun-06-23 04:30PM	Kiora Pharmaceuticals Announces Closing of $6.3 Million Underwritten Public Offering and Full Exercise of Over-Allotment Option (Newsfile) -7.53%
Jun-02-23 08:30AM	Kiora Pharmaceuticals Announces Pricing of $5.5 Million Underwritten Public Offering (Newsfile) -49.55%
May-09-23 07:00AM	Kiora Pharmaceuticals Reports First Quarter Results; Positive Clinical Data Driving Significant Progress Advancing Pipeline of Eye Disease Treatments (Newsfile)
May-01-23 07:00AM	Kiora Pharmaceuticals Presents Encore Imaging Results of KIO-301 for Retinitis Pigmentosa at ASNR 2023 Meeting (Newsfile) -10.36%
Apr-27-23 02:55PM	Kiora's Investigational Treatment for Retinitis Pigmentosa, KIO-301, Demonstrates Visual Function Restoration in Patients Who Are Blind (Newsfile) +8.90%
Apr-26-23 07:00AM	Kiora Pharmaceuticals' KIO-201 Heals Wounds in Phase 2 Trial of Patients with Persistent Corneal Epithelial Defects (Newsfile) +6.98%
Apr-21-23 07:00AM	Inherited Retinal Disease Expert, Mark Pennesi, M.D., Ph.D., Joins Kiora Pharmaceuticals' Scientific Advisory Board (Newsfile) +14.49%
Apr-17-23 07:00AM	Kiora Pharmaceuticals Initiates Phase 2 Trial of KIO-101 for the Treatment of Ocular Presentation of Autoimmune Diseases (Newsfile)
Mar-30-23 07:00AM	Kiora Announces the Acceptance of Late-Breaking Abstract on Phase 1b Study of KIO-301 in Retinitis Pigmentosa at The American Society of Neuroradiology 2023 Meeting (Newsfile)
Mar-23-23 07:00AM	Kiora Pharmaceuticals Reports 2022 Financial Results; Provides Update on Clinical Development Progress (Newsfile) -9.37%
Mar-10-23 07:00AM	Kiora Pharmaceuticals Announces the Acceptance of Three Abstracts at the 2023 ARVO Annual Meeting (Newsfile)
Feb-09-23 12:00PM	Biotech Stock Roundup: AMGN, GILD, BMY, REGN's Q4 Results, KPRX Up on Study Update (Zacks)
Feb-07-23 08:00AM	Kioras stock rallies as eye drop treatment moves into mid-stage clinical trial (MarketWatch) +38.72%
07:00AM	Kiora Pharmaceuticals Receives Investigational New Drug Approval for Phase 2 Study of KIO-101 for Treatment of Ocular Presentation of Autoimmune Diseases (Newsfile)
Feb-03-23 07:00AM	Kiora Pharmaceuticals Enters into Two Equity Purchase Agreements with Lincoln Park Capital (Newsfile)
Jan-09-23 07:00AM	Kiora Pharmaceuticals Highlights Anticipated Clinical and Corporate Milestones for 2023; Webcast Now Available on Company Website (Newsfile)
Jan-03-23 07:01AM	Kiora Pharmaceuticals Completes Enrollment of Clinical Trial Evaluating KIO-201 for Persistent Corneal Epithelial Defects; Results Expected to be Reported in 1H 2023 (Newsfile)
Dec-14-22 08:19AM	Stonegate Healthcare Reviews Retinitis Pigmentosa (Newsfile)
Nov-18-22 08:30AM	Kiora Pharmaceuticals Enters Into Agreements to Raise $3.12 Million From the Exercise of Previously Issued Class A Warrants (Newsfile) -35.85%
Nov-17-22 06:45AM	Kiora Pharmaceuticals Doses First Patient in ABACUS Phase 1b Study Evaluating KIO-301 for Retinitis Pigmentosa (Newsfile)

Kiora Pharmaceuticals, Inc. is a clinical-stage specialty pharmaceutical company, which engages in the development and commercialization of products for treating diseases and disorders of the eye. Its pipeline includes KIO-301, which is designed to restore vision in patients with inherited and age-related degenerative retinal disease, KIO-101 for patients with Ocular Presentation of Rheumatoid Arthritis, KIO-201 for patients undergoing PRK surgery for corneal wound repair after refractive surgery, and KIO-102. The company was founded in 1998 and is headquartered in Encinitas, CA.

PresidentDr. Brian M. Strem Ph.D.

Chief Financial OfficerMs. Melissa Tosca CPA

Executive Vice President of CMC & OperationsDr. Stefan Sperl Ph.D.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

KPRX

Kiora Pharmaceuticals Inc

Upgrade your Finviz experience